Leflunomid Bluefish (Leflunomide)

Leflunomide blocks the enzyme dihydroorotate dehydrogenase, which is essential for de novo pyrimidine synthesis. By limiting pyrimidine production, the drug reduces the proliferation of activated lymphocytes, thereby dampening the immune response that drives inflammation in rheumatoid and psoriatic arthritis.

The specific dosage regimen for Leflunomid Bluefish is determined by the prescribing physician based on the individual patient's condition, response, and tolerability. Healthcare professionals tailor the dose to achieve optimal therapeutic effect while monitoring safety.

Leflunomid Bluefish is classified as pregnancy category X, meaning it is contraindicated in pregnancy due to known risks of fetal harm. It is also not recommended for breastfeeding women because the drug can pass into breast milk and may affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Leflunomid Bluefish. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Leflunomid Bluefish offers a unique mechanism by inhibiting pyrimidine synthesis, differing from methotrexate which interferes with folate metabolism. This provides an alternative for patients who have inadequate response or intolerance to other conventional DMARDs, though safety profiles and monitoring requirements vary between agents.

Leflunomid Bluefish should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture. Keeping the product in a dry, ambient environment helps maintain its stability and potency throughout its shelf life.

The medication is taken orally, typically as a tablet swallowed with water. Patients should follow the prescribing physician’s instructions regarding timing, food intake, and any necessary dose adjustments.

Serious risks include severe liver injury, life‑threatening infections, bone marrow suppression, pulmonary toxicity, and rare but severe skin reactions such as Stevens‑Johnson syndrome. Prompt medical evaluation is essential if any signs of these conditions appear.

Leflunomid Bluefish is contraindicated in pregnant women, individuals with severe liver disease, uncontrolled infections, or known hypersensitivity to leflunomide. Patients with significant renal impairment or those taking certain interacting medications should also avoid or use the drug only under close medical supervision.